Veritas Asset Management’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Veritas Asset Management’s Portfolio CBPO Stock Details CBPO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-10,000	Closed	-$800K	–	31
2018 Q3	$800K	Hold	10,000	–	–	0.01%	27
2018 Q2	$993K	Buy	+10,000	New	+$864K	0.01%	29
2017 Q3	–	Sell	-15,000	Closed	-$1.7M	–	31
2017 Q2	$1.7M	Sell	15,000 -5,000	-25%	-$559K	0.01%	27
2017 Q1	$2M	Buy	+20,000	New	+$2.14M	0.02%	27

Other funds holding CBPO

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

YCMGA

York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Veritas Asset Management's CBPO Position: Q4 2018 in Review

Veritas Asset Management sold out of China Biologic Products Holdings, Inc. (CBPO) in Q4 2018, closing a stake of 10,000 shares — an estimated $800K sold.

Veritas Asset Management first reported a position in CBPO in Q1 2017 and held it in 4 quarters. The position peaked at $2M in Q1 2017. 67 funds tracked by Wall St. Rank hold CBPO as of Q4 2018.

Veritas Asset Management reported no remaining China Biologic Products Holdings, Inc. position as of Q4 2018 after selling out during the quarter.
Veritas Asset Management sold 10,000 China Biologic Products Holdings, Inc. shares in Q4 2018, an estimated $800K.
Veritas Asset Management first reported a position in China Biologic Products Holdings, Inc. in Q1 2017 and held it in 4 quarters.
Veritas Asset Management's China Biologic Products Holdings, Inc. position peaked at $2M in Q1 2017.
67 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q4 2018.

Based on Veritas Asset Management's 13F filing for Q4 2018, filed 12 Feb 2019.